

GenCore version 5.1.4-~~55~~-4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 27, 2003, 08:52:12 ; Search time 44 Seconds
(without alignments)
626.884 Million cell updates/sec

Title: Perfect score: US-09-836-960-5

Sequence: MYSAPSACTCCLCHFLLLCF. PKYVITVTKRSRRPRTHPA 207

Scoring table: BLOSUM62
Gapext 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: A_Geneseq_101002:*

2: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1980.DAT:*

3: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1982.DAT:*

4: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1983.DAT:*

5: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1985.DAT:*

6: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1986.DAT:*

7: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1987.DAT:*

8: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1988.DAT:*

9: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1989.DAT:*

10: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1990.DAT:*

11: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1992.DAT:*

12: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1991.DAT:*

13: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1993.DAT:*

14: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1994.DAT:*

15: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1995.DAT:*

16: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1996.DAT:*

17: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1997.DAT:*

18: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1998.DAT:*

19: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1999.DAT:*

20: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA2000.DAT:*

21: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA2001.DAT:*

22: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA2002.DAT:*

23: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/AA1986.DAT:*

RESULT 1
ID AA57413 standard; Protein: 207 AA.
AC AA57413;
XX DT 24-SEP-1998 (first entry)
DE Amino acid sequence of fibroblast growth factor homologue zFGF-5.
XX KW Human; fibroblast growth factor homologue; zFGF-5; cardiac cell; antagonist; antibody; heart failure; stroke; hypertension; cancer; bone defects; arthritis; cardiac myocyte hyperplasia.
XX PQ Homo sapiens.
XX PN WO9816644 A1.
XX PD 23-APR-1998.
XX PF 16-OCT-1997; 97WO-US18635.
XX PR 16-OCT-1996; 96US-0028646.
XX PA (ZYMO) ZYMOGENETICS INC.
XX PI Bukowski TR, Conklin DC, Deisher TA, Hansen B, Holderman SD;
Raymond FC, Sheppard PO;
WPI; 1998-251291/22.
DR N-PSDB; AAU29632.
XX PT New fibroblast growth factor homologue, zFGF-5 - used to develop

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1097	100.0	207 19	AAW57413
2	1097	100.0	207 20	AAV39628
3	1097	100.0	207 20	AAV08590
4	1097	100.0	207 21	AAI87857
5	1097	100.0	207 21	AAV44844
6	1097	100.0	207 21	AAV56817
7	1097	100.0	207 22	AGG65664
8	1097	100.0	207 22	AAB85827
9	1097	100.0	207 22	AAB04536
10	1097	100.0	207 22	AAU01240

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Need Rules ?

products for treating e.g. heart failure, stroke, hypertension, bone defects or cancers, arthritis, or wounds
 PT defcts or cancers, arthritis, or wounds
 XX
 PS Claim 14; Page 75; p 94pp; English.
 XX
 CC This is the amino acid sequence of the novel fibroblast growth factor homologue zfcf-5, used in the method of the invention. The zfcf-5 polypeptides can be used (optionally ex vivo) for enhancing the proliferation of cardiac tissue cells. The polypeptides, nucleic acids, antagonists, and antibodies can also be used in the treatment of disorders such as heart failure, stroke, hypertension, bone defects, cancer, arthritis, or wounds. The products can also be used in the study of cardiac myocyte hyperplasia and regeneration, to target delivery of agents to the heart and for detection and diagnosis. The recombinant agents can be used to produce the protein.
 CC
 XX Sequence 207 AA;

Query Match 100.0%; Score 1097; DB 19; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Delays 0;
 CC
 OY 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 Db 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 OY 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 Db 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 OY 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 Db 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 OY 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC
 Db 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC Sequence 207 AA;

PI Gospodarowicz D, Martin K;
 PT XX
 DR WPI: 1999-551410/46.
 DR N-PSDB; AR220593.
 XX
 PT New polynucleotide encoding a fibroblast growth factor, useful for treating peripheral neuropathy, Alzheimer's disease, ischaemic stroke, brain or spinal cord injury, nervous system tumours, multiple sclerosis, or epilepsy -
 XX
 PS Claim 5; Page 60; 60pp; English.
 CC
 CC This sequence is the human fibroblast growth factor 98 (FGF98) of the invention. FGF98 can be used for the isolation, regeneration, proliferation, and differentiation of mammalian multipotent neural stem cells, progenitor cells and progeny. Primary central (CNS) and peripheral nervous system (PNS) cells when treated with FGF98 proliferate, have at least a limited self regeneration capacity and can undergo lineage restriction in response to the local environment. The FGF98 sequences can be used for providing trophic support for cells in a patient. They be used to treat e.g. peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischaemic stroke, brain injury, acute spinal cord injury, nervous system tumours, multiple sclerosis, infection, dementia, epilepsy, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases, disorders of insufficient blood cells, retinits pigmentosa, age related macular degeneration, retinal detachment, myocardial ischaemia, infarction, peripheral vascular disease, renal artery disease and wound healing. Cells produced by treatment with FGF98 are also used to screen drugs and growth factors, which may affect development, differentiation, survival and/or function of CNS and PNS derived neurons and glia. FGF98 can also be used for the production of large amounts of otherwise minor populations of cells to be used for generation of cDNA libraries for the isolation of rare molecules expressed in precursor cells or progeny; cells produced by treatment may directly express growth factors or other molecules.

Query Match 100.0%; Score 1097; DB 20; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Delays 0;
 CC
 OY 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 Db 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 OY 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 Db 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 OY 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 Db 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 OY 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC
 Db 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC Sequence 207 AA;

RESULT 2
 AAY39628
 ID AAY39628 standard; Protein; 207 AA.
 XX
 AC AAY39628;
 XX
 DT 23-NOV-1999 (first entry)
 DE Human fibroblast growth factor 98 protein sequence.
 XX
 KW Fibroblast growth factor 98; FGF98; human; multipotent neural stem cell; progenitor cell; peripheral neuropathy; amyotrophic lateral sclerosis; Alzheimer's disease; Parkinson's disease; Huntington's disease; dementia; ischaemic stroke; brain injury; acute spinal cord injury; infection; nervous system tumour; multiple sclerosis; epilepsy; metabolic disease; peripheral nerve trauma; retinitis pigmentosa; macular degeneration; retinal detachment; myocardial infarction; peripheral vascular disease; renal artery disease; diagnosis; therapy.
 KW
 XX Sequence 207 AA;

Query Match 100.0%; Score 1097; DB 20; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11; Indels 0; Gaps 0;
 Matches 207; Conservative 0; Mismatches 0; Delays 0;
 CC
 OY 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 Db 1 MYSAPSACTCILCHFLICFOVQVLAENVDRIHENQNTARRDVSRSRKQLRYQLYSR 60
 OY 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 Db 61 TSGKHIQVLGRISARGEDGDKYAOQLVETDFFGSQRVKRGKPTRENQDVFHMKRYPK 120
 OY 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 Db 121 DGTSKECVFIEKVLENNY-TALMSAKSY-SWY-GFTKKGRPRKGPKTRENQDVFHMKRYPK 180
 OY 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC
 Db 181 GOPELOKPFKPYTVTKRSRRPRTHPA 207
 CC Sequence 207 AA;

RESULT 3
 AAY08590
 ID AAY08590 standard; Protein; 207 AA.
 XX
 AC AAY08590;
 XX
 DT 05-AUG-1999 (first entry)
 DE Human FGF-18 protein fragment.
 XX
 KW PRO533; FGF-19; fibroblast growth factor; human; diagnosis; treatment; tumour; neoplastic cell growth; cell proliferation; tumorigenesis; cancer; autocrine signalling; FGF-18.

PR 29-APR-1998; 98US-0083553.
 PR 08-MAR-1999; 99US-0264851.
 XX
 PA (CHIR) CHIRON CORP.
 XX
 PI Cen H, Garcia PN, Griesammer U, Kassam A, Lee PP, Pot D;

KW FGF-98; fibroblast growth factor; cardiant; treatment; angiogenesis;
RW coronary artery disease; myocardial infarction injury; human.
OS Homo sapiens.

XX WO9927100-A1.
PN 03-JUN-1999.
XX FF 25-NOV-1998; 98WO-US25190.
PR 21-SEP-1998; 98US-0158432.
PR 25-NOV-1997; 97US-0066840.
XX PR (GEPH) GENENTECH INC.
XX PI Botstein D, Goddard A, Gurney AL, Hillan KJ, Lawrence DA;
PT ROY MA;
XX DR WPI; 1999-347718/29.

XX PT Nucleic acid encoding fibroblast growth factor - 19, useful for the
PT diagnosis, prevention and treatment of cancers
XX Disclosure; Fig 11; 88pp; English.
XX This invention describes a novel human fibroblast growth factor, PRO533,
CC also known as fibroblast growth factor-19 (FGF-19). The nucleic acids,
CC methods and PRO33 polypeptides disclosed may be used in the diagnosis,
CC and treatment of tumours and/or conditions characterized by modulation of
PRO33 expression, or in the preparation of compositions for such
therapies. These compositions and methods may be used in the diagnosis
CC and treatment of neoplastic cell growth and proliferation in mammals
(especially humans). The invention is based on the identification of
CC genes that are amplified in the genome of tumor cells. Such gene
CC amplification is expected to be associated with the over expression of
CC the gene product and contribute to tumourgenesis and/or autocrine
CC signalling. Accordingly, the proteins encoded by the amplified genes are
CC believed to be useful targets for the diagnosis and/or treatment of
CC certain cancers and may act as predictors of the prognosis for tumour
CC treatments.
XX Sequence 207 AA;

Query Match 100.0%; Score 1097; DB 20; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-11; Indels 0; Gaps 0;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MYSAPSACTCLCLHLFLLCFOVQLVAEENDRIRHVNQTRARDVSKRQLRYOLYSR 60
Db 1 MYSAPSACTCLCLHLFLLCFOVQLVAEENDRIRHVNQTRARDVSKRQLRYOLYSR 60

Qy 61 TSGKHIQVIGRISARGEDGDKYQQLVETDTGSQVRIGKEPEFYLCMNRKGLVKRP 120
Db 61 TSGKHIQVIGRISARGEDGDKYQQLVETDTGSQVRIGKEPEFYLCMNRKGLVKRP 120

Qy 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180
Db 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180

Qy 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207
Db 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207

Qy 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180
Db 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180

Qy 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207
Db 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207

RESULT 4
AY87857
ID AY87857 standard; protein; 207 AA.
XX
AC AAY87857;
XX
DT 01-SEP-2000 (first entry)
XX
DE Human FGF-98 protein fragment.
XX

XX KW FGF-98; fibroblast growth factor; cardiant; treatment; angiogenesis;
XX RW coronary artery disease; myocardial infarction injury; human.
XX OS Homo sapiens.
XX PN WO20021548-A2.
XX DR 20-APR-2000.
XX PR 13-OCT-1999; 99WO-US22936.
XX PR 13-OCT-1998; 98US-0104103.
XX PA (CHIR) CHIRON CORP.
PA (WHITEHOUSE M J .
PI Kavanaugh WM;
XX DR WPI; 2000-31740/27.
XX PS Claim 1; Page 65-66; 67pp; English.
XX This invention describes a novel unit dose (I), of fibroblast growth
CC factor (FGF) comprising 0.008-6.1 mg of a mammalian FGF comprising
CC sequence of I40 ((II) and (III)), 146 ((IV) and (V)), 205 (VI), 266
CC ((VII), 207 ((VIII) and (XI)), 215 (IX), and 20 (X) amino acids (aa),
CC given in the specification, its angiogenically active fragment or
mutant. The product of the invention has angiogenic and cardiant
activity. (I) is used for treating a human patient for coronary artery
CC disease, and inducing angiogenesis in the human heart. (I) further
provides an adjunct for reducing post myocardial infarction injury in
CC humans. The unit dose provides the human patient with a rapid and
CC therapeutic cardiac angiogenesis sufficient to obviate surgical
intervention and results in an superior increase in the treated
CC patient's exercise tolerance time (ERT). It also provides a safe and
therapeutically efficacious treatment for the patients with coronary
CC artery disease that lasts at least 6 months before a further treatment
is needed. The method provides superior increase of 1.5-2 minutes in
CC the treated patient's (ERT), compared to an increase of 30 seconds for
CC current modes treatment. This represents the human FGF-98
protein fragment described in the method of the invention.
XX Sequence 207 AA;

Query Match 100.0%; Score 1097; DB 21; Length 207;
Best Local Similarity 100.0%; Pred. No. 9.3e-11; Indels 0; Gaps 0;
Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MYSAPSACTCLCLHLFLLCFOVQLVAEENDRIRHVNQTRARDVSKRQLRYOLYSR 60
Db 1 MYSAPSACTCLCLHLFLLCFOVQLVAEENDRIRHVNQTRARDVSKRQLRYOLYSR 60

Qy 61 TSGKHIQVIGRISARGEDGDKYQQLVETDTGSQVRIGKEPEFYLCMNRKGLVKRP 120
Db 61 TSGKHIQVIGRISARGEDGDKYQQLVETDTGSQVRIGKEPEFYLCMNRKGLVKRP 120

Qy 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180
Db 121 DGTSKECVIEKVLENNNTALMSAKYSGWYGTGKGRPKTRENOQDVFHEMKRPK 180

Qy 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207
Db 181 GQPELQKPKFYTWTKRSSRRIRPHPA 207

RESULT 5
AY4844
ID AY4844 standard; Protein; 207 AA.

DE Human fibroblast growth factor (zFGF5).
 XX
 KW Human; fibroblast growth factor-18; zFGF-18; FGF receptor-2;
 KW FGF receptor-3; cytotoxin; cell proliferation inhibitor; tumour;
 KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
 KW thyroid carcinoma; osteosarcoma.
 XX OS Homo sapiens.

Key Location/Qualifiers
 FT Peptide 1..27
 FT Protein 28..207
 FT *note= "Human mature fibroblast growth factor (zFGF5)"*
 PN WO200139788-A2.
 XX PD 07-JUN-2001.
 XX PF 28-NOV-2000; 2000WO-US32380.
 XX PR 02-DEC-1999; 99US-0452977.
 XX PA (ZYMO) ZYMOGENETICS INC.
 XX PI West JW;
 XX DR WPI; 2001-417789/44.
 DR N-PSDB; AAD7795.
 XX PT Novel fibroblast growth factor targeting composition useful for
 PT inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
 XX receptor 2 -
 PS Claim 3: Page 59; 62pp; English.

CC The present invention relates to methods for targetting cells that
 CC express fibroblast growth receptor-3 or -2. Fibroblast growth
 CC factor-18 (FGF-18) binds with FGF receptor-2 and -3. A targetting
 CC composition comprising FGF-18 component and cytotoxin, is useful for
 CC inhibiting the proliferation of cells that express FGF receptor-3 or
 CC -2, in a subject having tumour cells such as multiple myeloma cells,
 CC bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
 CC cells, osteosarcoma cells and intimal smooth muscle cells. The present
 CC sequence is human zFGF5 protein.
 SQ Sequence 207 AA:
 Query Match 100.0%; Score 1097; DB 22; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTCCLHLFLICFOQVQLVAEENNDFRIVENOTRARDVSKQRQLRYLYSR 60
 DB 1 MYSAPSACTCCLHLFLICFOQVQLVAEENNDFRIVENOTRARDVSKQRQLRYLYSR 60
 QY 61 TSGKHTQVLGRISARGEDGDKYAQOLIVEDTFSQVRKGKETEFYLCMNRKGKLVGP 120
 DB 61 TSGKHTQVLGRISARGEDGDKYAQOLIVEDTFSQVRKGKETEFYLCMNRKGKLVGP 120
 QY 121 DGTSKCQVFLKVENNYTALMSAKYSGWVGFITKKGRPRKGPKTRENQDVFHMKRYPK 180
 DB 121 DGTSKCQVFLKVENNYTALMSAKYSGWVGFITKKGRPRKGPKTRENQDVFHMKRYPK 180
 QY 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 DB 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 QY 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 DB 181 GQPELQKPKFTTVTKRSRIRTPHA 207

RESULT 10
 AAU01240
 ID AAU01240 standard; Protein; 207 AA.

AC AAU01240;
 XX DT 16-JUL-2001 (first entry)
 XX DE Human fibroblast growth factor homologue, zFGF-5.
 XX KW Human; fibroblast growth factor homologue; zFGF-5; plasmid construction;
 KW homologous recombination.
 XX OS Homo sapiens.

Key Location/Qualifiers
 FT Peptide 1..26
 FT *note= "Signal peptide"*
 FT Protein 27..207
 FT *label= Mature_zFGF-5*

XX PN US6207442-B1.
 XX PD 27-MAR-2001.
 XX PF 15-OCT-1998; 98US-0173043.
 XX PR 16-OCT-1997; 97US-0062061.
 XX PA (ZYMO) ZYMOGENETICS INC.
 XX PI Raymond CK;
 XX DR N-PSDB; AAS00951.
 XX PT Preparing a double-stranded, circular DNA molecule, involves homologous
 PT recombination of one or more donor DNA fragments encoding the protein
 PT of interest, with an acceptor plasmid and DNA linkers in host cell -
 XX PS Example 5; Columns 27-30; 23pp; English.

The sequence is a Human fibroblast growth factor homologue, zFGF-5, used to demonstrate the method of the invention. The method of the invention comprises preparing a double-stranded, circular DNA molecule, comprising combining donor DNA fragments encoding the protein of interest, with an acceptor plasmid, and two DNA linkers in a *Saccharomyces cerevisiae* host cell. The encoding DNA is linked to the acceptor plasmid by homologous recombination of with the linkers and acceptor plasmid to form the closed, circular plasmid. The obtained plasmid is useful for transforming host cells and producing proteins of interest. The method allows for production of a standardised plasmid into which a variety of CC DNA sequences can be readily inserted and subsequently expressed.

XX SQ Sequence 207 AA:
 Query Match 100.0%; Score 1097; DB 22; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11;
 Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MYSAPSACTCCLHLFLICFOQVQLVAEENNDFRIVENOTRARDVSKQRQLRYLYSR 60
 DB 1 MYSAPSACTCCLHLFLICFOQVQLVAEENNDFRIVENOTRARDVSKQRQLRYLYSR 60
 QY 61 TSGKHTQVLGRISARGEDGDKYAQOLIVEDTFSQVRKGKETEFYLCMNRKGKLVGP 120
 DB 61 TSGKHTQVLGRISARGEDGDKYAQOLIVEDTFSQVRKGKETEFYLCMNRKGKLVGP 120
 QY 121 DGTSKCQVFLKVENNYTALMSAKYSGWVGFITKKGRPRKGPKTRENQDVFHMKRYPK 180
 DB 121 DGTSKCQVFLKVENNYTALMSAKYSGWVGFITKKGRPRKGPKTRENQDVFHMKRYPK 180
 QY 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 DB 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 QY 181 GQPELQKPKFTTVTKRSRIRTPHA 207
 DB 181 GQPELQKPKFTTVTKRSRIRTPHA 207

RESULT 11
 AAET8823 DT AAFI8823 standard; Protein; 207 AA.
 XX AC AAEI8823;
 XX DT 17-MAY-2002 (first entry)
 XX DE Human FGF-18 protein.

KW Fibroblast growth factor; FGF-like protein; wound healing; bullous epidermolysis; erosive gastritis; inflammatory bowel disease; ulcer; oesophagitis; Crohn's disease; hyaline membrane disease; emphysema; pulmonary fibrosis; hepatic cirrhosis; liver failure; angiogenesis; multiple sclerosis; neurodegenerative disease; lung abnormality; viral hepatitis; respiratory distress syndrome; tumour; skin aging; gene therapy; vaccine; human.

KW Homo sapiens.

OS XX US2002001825-A1.

XX PD 03-JAN-2002.

XX PF 02-APR-2001; 2001US-0822485.

XX PR 31-MAR-2000; 2000US-0540118.

XX PA (ITOH/) ITOH N.

PT ITOH N;

XX WPI; 2002-187704/24.

XX Novel fibroblast growth factor-like polypeptide useful for treating, ameliorating and/or preventing dermal wounds, gastric ulcer, Crohn's disease and pulmonary inflammation - Disclosure; Fig 3; 63pp; English.

XX The invention relates to fibroblast growth factor (FGF)-like polypeptides and nucleic acid molecules encoding such polypeptides. Sequences of the invention are useful for treating, preventing or ameliorating a medical condition. They are useful for treating dermal wounds, epidermolysis, bullous, male pattern alopecia, gastric ulcer, duodenal ulcer, erosive gastritis, oesophagitis, oesophageal reflux disease, inflammatory bowel disease, Crohn's disease, radiation- or chemotherapy-induced gut toxicity, hyaline membrane disease, necrosis of the respiratory epithelium, emphysema, pulmonary inflammation, pulmonary fibrosis, hepatic cirrhosis, toxic insults to the liver, fulminant liver failure, viral hepatitis, mucositis, multiple sclerosis and other neurodegenerative diseases, infantile respiratory distress syndrome, bronchopulmonary dysplasia, acute respiratory distress syndrome or other lung abnormalities, tumours of the eye or the other tissues and organs. FGF-like polypeptides are useful stimulating angiogenesis, promoting wound healing, modulating differentiation of neuronal cells, adipocytes and skeletal muscle cells, preventing or ameliorate skin aging, preventing hair loss, stimulating the growth and differentiation of haematopoietic cells and bone marrow cells and maintaining organs before transplantation and for supporting cultures of primary cells and tissues. Sequences of the invention are also used in gene therapy and as vaccines. The present sequence is human FGF-18 protein which is a member of the FGF family.

XX Sequence 207 AA;

Query Match 100.0%; Score 1097; DB 23; Length 207;
 Best Local Similarity 100.0%; Pred. No. 9.3e-11; DB Matches 207; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSAPSACTCLCILHFLLCFOVQVLAEEENPVRIHVENOTRARDYDSRKQLRYOLYSR 60
 1 MSAPSACTCLCILHFLLCFOVQVLAABENVDPRHVENOTRARDYDSRKQLRYOLYSR 60
 SQ Sequence 207 AA;

Query Match 98.5%; Score 1081; DB 21; Length 207;
 Best Local Similarity 99.0%; Pred. No. 5.1e-109; DB Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MYAPSACTCLCILHFLLCFOVQVLAEEENPVRIHVENOTRARDYDSRKQLRYOLYSR 60
 1 MSAPSACTCLCILHFLLCFOVQVLAABENVDPRHVENOTRARDYDSRKQLRYOLYSR 60
 SQ 61 TSCHKHQIGRRISARGGDGDKYAQQLMWTDTGGSQVMIKGKTEFYCMNRKGKLYQKP 120
 61 TSCHKHQIGRRISARGGDGDKYAQQLMWTDTGGSQVMIKGKTEFYCMNRKGKLYQKP 120
 DB 61 DGTSKECUTIEKYLENNNTALMSAKYSGWIVGFTKKGRPKGKTRENOQDVHFMKRP 180
 DB 121 DGTSKECUTIEKYLENNNTALMSAKYSGWIVGFTKKGRPKGKTRENOQDVHFMKRP 180
 QY 181 GQPLQKPFKTYTWRKSRIRIPTP 206

DE 181 GQTELQKPFKVTVTKRSRRIRPTHP 206
 RESULT 13
 AAY56819 standard; Protein: 207 AA.
 ID AAY56819;
 XX
 AC
 XX
 DT 31-MAR-2000 (first entry)
 DE Mouse fibroblast growth factor (FGF).
 XX
 KW Fibroblast growth factor; FGF; FGF-23; osteopathic; vulnerability; ADHR;
 KW hepatotrophic; autosomal dominant hypophosphatemic rickets; mouse;
 KW angiogenesis; gene-therapy; liver disorder; antisense-therapy.
 XX
 OS MUS musculus.
 XX
 PN WO200161007-A2.
 PD 23-AUG-2001.
 XX
 PF 15-FEB-2001; 2001WO-US04778.
 XX
 PR 15-FEB-2000; 2000US-0182442.
 PR 20-APR-2000; 2000US-0198903.
 PR 15-FEB-2001; 2001US-0748581.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Luethy R, Yang R, Suggs S, Sarosi D;
 XX
 DR WPI; 2001-514774/56.
 XX
 PT An isolated nucleic acid molecule encoding a fibroblast growth factor -
 PT 23 useful for treating autosomal dominant hypophosphatemic rickets -
 XX
 PS Example 1; Fig 2A-G; 158pp; English.
 XX
 CC The invention provides a human fibroblast growth factor (FGF)-23
 CC polypeptide. The encoding DNA insert is contained in ATCC Deposit No.
 CC PTA-1617. FGF-23 can be expressed by standard recombinant methodology.
 CC The FGF-23 polypeptides, polynucleotides, modulators and antibodies are
 CC useful for treating, preventing or ameliorating an FGF-23 polypeptide-
 CC related disease, condition or disorder especially autosomal dominant
 CC hypophosphatemic rickets (ADHR). They are also useful for diagnosing a
 CC pathological condition and for stimulating angiogenesis, promoting wound
 CC healing and treating disorders of the liver. Sequences AAB05830-45
 CC represent murine FGF protein sequences used for comparison studies with
 CC human FGF-23.
 XX
 SQ Sequence 207 AA:

Query Match	Score 98.5%	Length 21	Score 1081	DB 21	Length 207
Best Local Similarity	99.0%	Pred. No. 5.1e-109			
Matches 204;	Conservative	0;	Mismatches	2;	Indels 0;
					Gaps 0;

QY 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 Db 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 QY 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 Db 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 QY 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 Db 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 QY 181 GQPELOKPKFTTVKRSRRIRPTHP 206
 Db 181 GQAELOKPKFTTVKRSRRIRPTHP 206
 . . .
 SQ Sequence 207 AA:

Query Match	Score 98.5%	Length 22	Score 1081	DB 22	Length 207
Best Local Similarity	99.0%	Pred. No. 5.1e-109			
Matches 204;	Conservative	0;	Mismatches	2;	Indels 0;
					Gaps 0;

QY 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 Db 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 QY 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 Db 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 QY 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 Db 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 QY 181 GQPELOKPKFTTVKRSRRIRPTHP 206
 Db 181 GQAELOKPKFTTVKRSRRIRPTHP 206
 . . .
 SQ Sequence 207 AA:

Query Match	Score 98.5%	Length 21	Score 1081	DB 21	Length 207
Best Local Similarity	99.0%	Pred. No. 5.1e-109			
Matches 204;	Conservative	0;	Mismatches	2;	Indels 0;
					Gaps 0;

QY 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 Db 1 MYSAPSACTCTCLHFLLCFOQVLAENDFRIVENOTRARDVSRKQLRLQLYSR 60
 QY 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 Db 61 TSGKHTQVLGRRIISARGEDEGDKYAQOLIVETDIFGSQVRIGKKETEFYLCMNRKGKLVGKP 120
 QY 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 Db 121 DGTSKBCVFIEKVLNNNTALMSAKYSGWVYGFTRKGRPKRGPKTRENOQDVHEMKRYPK 180
 QY 181 GQPELOKPKFTTVKRSRRIRPTHP 206
 Db 181 GQAELOKPKFTTVKRSRRIRPTHP 206
 . . .
 RESULT 14
 AAB8545 standard; Protein: 207 AA.
 ID AAB8545;
 XX
 AC AAB8545;
 XX
 DT 29-OCT-2001 (first entry)
 DE Mouse fibroblast growth factor (zFGF5).

XX
 KW Mouse; fibroblast growth factor-18; zFGF5; FGF receptor-2;
 KW FGF receptor-3; cytoxin; cell proliferation inhibitor; tumour;
 KW multiple myeloma; bladder carcinoma; cervix carcinoma; cytostatic;
 KW thyroid carcinoma; osteosarcoma.
 XX OS Mus musculus.
 XX PN WO200139788-A2.
 XX PD 07-JUN-2001.
 XX PF 28-NOV-2000; 2000MO-US32380.
 XX PR 02-DEC-1999; 99US-0452977.
 XX PA (ZYMO) ZYMOGENETICS INC.
 XX PI West JW;
 XX DR WPI; 2001-417789/44.
 DR N-PSDB; AAD07796.
 XX Novel fibroblast growth factor targeting composition useful for
 PR inhibiting the proliferation of cells expressing FGF receptor 3 or FGF
 PT receptor 2.
 XX
 PS Claim 4: Page 61-62; 62pp; English.
 XX
 CC The present invention relates to methods for targetting cells that
 CC express fibroblast growth receptor-3 or -2. Fibroblast growth
 CC factor -18 (zFGF-18) binds with FGF receptor-2 and -3. A targetting
 CC composition comprising FGF-18 component and cytoxin, is useful for
 CC inhibiting the proliferation of cells that express FGF receptor-3 or
 CC -2, in a subject having tumour cells such as multiple myeloma cells,
 CC bladder carcinoma cells, cervix carcinoma cells, thyroid carcinoma
 CC cells, osteosarcoma cells and intimal smooth muscle cells. The present
 CC sequence is mouse zFGF5 protein.
 XX Sequence 207 AA:
 Query Match 98.5%; Score 1081; DB 22; Length 207;
 Best Local Similarity 99.0%; Pred. No. 5.1e-109;
 Matches 204; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 MSAPSACTCLCFLLCFOQVQLVAENVPRIHVNQTRADDYSRKQLRYQIYSR 60
 Db 1 MSAPSACTCLCFLLCFOQVQLVAENVPRIHVNQTRADDYSRKQLRYQIYSR 60
 QY 61 TSSKHIQVLGRITSARGEDGDKYAQQLVETDIFGSQVRIGKRETERYLCMNRKGLVGKP 120
 Db 61 TSSKHIQVLGRITSARGEDGDKYAQQLVETDIFGSQVRIGKRETERYLCMNRKGLVGKP 120
 QY 121 DGTSKECVFIKEVLLENNTTALMSAKYSCWYGETKKGRPRKPKTRENQDQDHFMKYPK 180
 Db 121 DGTSKECVFIKEVLLENNTTALMSAKYSCWYGETKKGRPRKPKTRENQDQDHFMKYPK 180
 QY 181 GQPPELOPKEPKYTVTKRSRRIRTPH 206
 Db 181 GQAELOPKEPKYTVTKRSRRIRTPH 206

Search completed: April 27, 2003, 15:03:24
 Job time : 46 secs

THIS PAGE BLANK (USPTO)